Management of bleeding emergencies

When to use recombinant activated Factor VII

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    Recombinant activated Factor VII (rVIIa) was originally released as a clotting factor, with use limited to a select group of patients who had few other treatment options. Due to the apparent ability of rVIIa to stop bleeding, no matter what the underlying cause, there is great interest in use of rVIIa in a wide range of bleeding patients. This article discusses rVIIa and its uses in a variety of patients, especially liver disease and trauma patients, and makes suggestions for appropriate use. Although most of the reports on rVIIa are anecdotes and case series, there is increasing data for clinical trials to help guide usage.

    Original languageEnglish (US)
    Pages (from-to)25-34
    Number of pages10
    JournalExpert Opinion on Pharmacotherapy
    Volume7
    Issue number1
    DOIs
    StatePublished - Jan 2006

    Fingerprint

    Factor VIIa
    Emergencies
    Hemorrhage
    Anecdotes
    Blood Coagulation Factors
    Liver Diseases
    Clinical Trials
    Wounds and Injuries
    Therapeutics

    Keywords

    • Bleeding emergencies
    • Haemorrhage
    • Recombinant activated Factor VII
    • Transfusion

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Pharmacology, Toxicology and Pharmaceutics(all)

    Cite this

    Management of bleeding emergencies : When to use recombinant activated Factor VII. / Deloughery, Thomas.

    In: Expert Opinion on Pharmacotherapy, Vol. 7, No. 1, 01.2006, p. 25-34.

    Research output: Contribution to journalArticle

    @article{62143e99d8684953875d558cbda9f1dc,
    title = "Management of bleeding emergencies: When to use recombinant activated Factor VII",
    abstract = "Recombinant activated Factor VII (rVIIa) was originally released as a clotting factor, with use limited to a select group of patients who had few other treatment options. Due to the apparent ability of rVIIa to stop bleeding, no matter what the underlying cause, there is great interest in use of rVIIa in a wide range of bleeding patients. This article discusses rVIIa and its uses in a variety of patients, especially liver disease and trauma patients, and makes suggestions for appropriate use. Although most of the reports on rVIIa are anecdotes and case series, there is increasing data for clinical trials to help guide usage.",
    keywords = "Bleeding emergencies, Haemorrhage, Recombinant activated Factor VII, Transfusion",
    author = "Thomas Deloughery",
    year = "2006",
    month = "1",
    doi = "10.1517/14656566.7.1.25",
    language = "English (US)",
    volume = "7",
    pages = "25--34",
    journal = "Expert Opinion on Pharmacotherapy",
    issn = "1465-6566",
    publisher = "Informa Healthcare",
    number = "1",

    }

    TY - JOUR

    T1 - Management of bleeding emergencies

    T2 - When to use recombinant activated Factor VII

    AU - Deloughery, Thomas

    PY - 2006/1

    Y1 - 2006/1

    N2 - Recombinant activated Factor VII (rVIIa) was originally released as a clotting factor, with use limited to a select group of patients who had few other treatment options. Due to the apparent ability of rVIIa to stop bleeding, no matter what the underlying cause, there is great interest in use of rVIIa in a wide range of bleeding patients. This article discusses rVIIa and its uses in a variety of patients, especially liver disease and trauma patients, and makes suggestions for appropriate use. Although most of the reports on rVIIa are anecdotes and case series, there is increasing data for clinical trials to help guide usage.

    AB - Recombinant activated Factor VII (rVIIa) was originally released as a clotting factor, with use limited to a select group of patients who had few other treatment options. Due to the apparent ability of rVIIa to stop bleeding, no matter what the underlying cause, there is great interest in use of rVIIa in a wide range of bleeding patients. This article discusses rVIIa and its uses in a variety of patients, especially liver disease and trauma patients, and makes suggestions for appropriate use. Although most of the reports on rVIIa are anecdotes and case series, there is increasing data for clinical trials to help guide usage.

    KW - Bleeding emergencies

    KW - Haemorrhage

    KW - Recombinant activated Factor VII

    KW - Transfusion

    UR - http://www.scopus.com/inward/record.url?scp=30344443937&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=30344443937&partnerID=8YFLogxK

    U2 - 10.1517/14656566.7.1.25

    DO - 10.1517/14656566.7.1.25

    M3 - Article

    VL - 7

    SP - 25

    EP - 34

    JO - Expert Opinion on Pharmacotherapy

    JF - Expert Opinion on Pharmacotherapy

    SN - 1465-6566

    IS - 1

    ER -